Human cleft lip and palate fibroblasts and normal nicotine-treated fibroblasts show altered in vitro expressions of genes related to molecular signaling pathways and extracellular matrix metabolism

Journal of Cellular Physiology

Volumn 222, Issue 3, 2010, Pages 748-756

  Baroni, Tiziano ^a   Bellucci, Catia ^a   Lilli, Cinzia ^a   Pezzetti, Furio ^b   Carinci, Francesco ^c   Lumare, Eleonora ^a   Palmieri, Annalisa ^b   Stabellini, Giordano ^d   Bodo, Maria ^a  

^a UNIVERSITY OF PERUGIA   (Italy)

^b UNIVERSITY OF BOLOGNA   (Italy)

^c UNIVERSITY OF FERRARA   (Italy)

^d UNIVERSITY OF MILAN   (Italy)

Author keywords

[No Author keywords available]

Indexed keywords

ALPHA2 INTEGRIN; BETA5 INTEGRIN; COLLAGENASE 3; DECORIN; FIBRONECTIN; HERMES ANTIGEN; NICOTINE; RETINOIC ACID; SYNDECAN; TRANSFORMING GROWTH FACTOR BETA;

ARTICLE; CELL CULTURE; CELL METABOLISM; CHILD; CHOLINERGIC SYSTEM; CLEFT LIP; CLEFT PALATE; CLINICAL ARTICLE; CLPTM1 GENE; COMPARATIVE STUDY; CONTROLLED STUDY; DEVELOPMENT; DISEASE COURSE; EXTRACELLULAR MATRIX; FIBROBLAST; GABAERGIC SYSTEM; GENE; GENE EXPRESSION; HUMAN; HUMAN CELL; HUMAN TISSUE; IN VITRO STUDY; MALE; NUCLEOTIDE SEQUENCE; PALATE; PHENOTYPE; PRIORITY JOURNAL; QUANTITATIVE ANALYSIS; REAL TIME POLYMERASE CHAIN REACTION;

CASE-CONTROL STUDIES; CELL SHAPE; CELL SURVIVAL; CELLS, CULTURED; CHILD, PRESCHOOL; CLEFT LIP; CLEFT PALATE; EXTRACELLULAR MATRIX; FIBROBLASTS; GENE EXPRESSION PROFILING; GENE EXPRESSION REGULATION; GENOTYPE; HUMANS; MALE; NICOTINE; NICOTINIC AGONISTS; PHENOTYPE; REVERSE TRANSCRIPTASE POLYMERASE CHAIN REACTION; SIGNAL TRANSDUCTION;

EID: 73649107592     PISSN: 00219541     EISSN: None     Source Type: Journal    
DOI: 10.1002/jcp.22006     Document Type: Article

References (40)

1. Arpino C, Brescianini S, Robert E, Castilla EE, Cocchi G, Cornel MC, de Vigan C, Lancaster PA, Merlob P, Sumiyoshi Y, Zampino G, Renzi C, Rosano A, Mastroiacovo P. 2000. Teratogenic effects of antiepileptic drugs: Use of an international database on malformations and drug exposure (MADRE). Epilepsia 41:1436-1443.
2. Arredondo J, Hall LL, Ndoye A, Nguyen VT, Chernyavsky AI, Bercovich D, Orr-Urtreger A, Beaudet AL, Grando SA. 2003. Central role of fibroblast alpha3 nicotinic acetylcholine receptor in mediating cutaneous effects of nicotine. Lab Invest 83:207-225.
3. Baroni T, Carinci P, Bellucci C, Lilli C, Becchetti E, Carinci F, Stabellini G, Pezzetti F, Caramelli E, Tognon M, Bodo M. 2003. Cross-talk between interleukin-6 and transforming growth factor-beta3 regulates extracellular matrix production by human fibroblasts from subjects with non-syndromic cleft lip and palate. J Periodont 74:1447-1453.
4. Baroni T, Bellucci C, Lilli C, Pezzetti F, Carinci F, Becchetti E, Carinci P, Stabellini G,Calvitti M, Lumare E, Bodo M. 2006. Retinoic acid, GABA-ergic, and TGF-beta signaling systems are involved in human cleft palate fibroblast phenotype. Mol Med 12:237-245.
5. Blavier L, Lazaryev A, Groffen J, Heisterkamp N, DeClerck YA, Kaartinen V. 2001. TGF-beta3-induced palatogenesis requires matrix metalloproteinases. Mol Biol Cell 12:1457-1466.
6. Bodo M, Baroni T, Carinci F, Becchetti E, Bellucci C, Pezzetti F, Conte C, Evangelisti R, Carinci P. 1999. TGFbeta isoforms and decorin gene expression are modified in fibroblasts obtained from non-syndromic cleft lip and palate subjects. J Dent Res 78:1783-1790.
7. Bosi G, Evangelisti R, Valeno V, Carinci F, Pezzetti F, Calastrini C, Bodo M, Carinci P. 1998. Diphenylhydantoin affects glycosaminoglycans and collagen production by human fibroblasts from cleft palate patients. J Dent Res 77:1613-1621.
8. Carinci F, Pezzetti F, Scapoli L, Martinelli M, Avantaggiato A, Carinci P, Padula E, Baciliero U, Gombos F, Laino G, Rullo R, Cenzi R, Carls F, Tognon M. 2003. Recent developments in orofacial cleft genetics. J Craniofac Surg 14:130-143.
9. Carinci F, Scapoli L, Palmieri A, Zollino I, Pezzetti F. 2007. Human genetic factors in nonsyndromic cleft lip and palate:An update. Int J Pediatr Otorhinolaryngol 71:1509-1519.
10. Carlisle DL, Hopkins TM, Gaither-Davis A, Silhanek MJ, Luketich JD, Christie NA, Siegfried JM. 2004. Nicotine signals through muscle-type and neuronal nicotinic acetylcholine receptors in both human bronchial epithelial cells and airway fibroblasts. Respir Res 10:5-27.
11. Cohen MM Jr. 1991. Etiopathogenesis of craniosynostosis. Neurosurg Clin N Am2:507-513.
12. Conti-Fine BM, Navaneetham D, Lei S, Maus AD. 2000. Neuronal nicotinic receptors in non-neuronal cells: New mediators of tobacco toxicity? Eur J Pharmacol 393:279-294.
13. Cucina A, Corvino V, Sapienza P, Borrelli V, Lucarelli M, Scarpa S, Strom R, Santoro-D'Angelo L, Cavallaro A. 1999. Nicotine regulates basic fibroblastic growth factor and transforming growth factor beta1 production in endothelial cells. Biochem Biophys Res Commun 257:306-312.
14. Ding R, Tsunekawa N, Obata K. 2004. Cleft palate by picrotoxin or 3-MP and palatal shelf elevation in GABA-deficient mice. Neurotoxicol Teratol 26:587-592.
15. Grando SA, Kist D, Qi M, Dahl M. 1993. Human keratinocytes synthesize, secrete, and degrade acetylcholine. J Invest Dermatol 101:32-36.
16. Jin JZ, Li Q,Higashi Y,Darling DS, Ding J. 2008. Analysis of Zfhx1a mutantmice reveals palatal shelf contact-independent medial edge epithelial differentiation during palate fusion. Cell Tissue Res 333:29-38.
17. Kaartinen V, Voncken JW, Shuler C, Warburton D, Bu D, Heisterkamp N, Groffen J. 1995. Abnormal lung development and cleft palate in mice lacking TGF-beta 3 indicates defects of epithelial-mesenchymal interaction. Nat Genet 11:415-421.
18. Kang P, Svoboda KK. 2003. Nicotine inhibits palatal fusion and modulates nicotinic receptors and the PI-3 kinase pathway in medial edge epithelia. Orthod Craniofac Res 6:129-142.
19. Kavsak P, Rasmussen RK, Causing CG, Bonni S, Zhu H, Thomsen GH, Wrana JL. 2000. Smad7 binds to Smurf2 to form an E3 ubiquitin ligase that targets the TGF-beta receptor for degradation. Mol Cell 6:1365-1375.
20. Kresse H, Schönherr E. 2001. Proteoglycans of the extracellular matrix and growth control. J Cell Physiol 189:266-274.
21. Little J, Cardy A, Arslan MT, Gilmour M, Mossey PA. 2004. Smoking and orofacial clefts: A United Kingdom-based case-control study. Cleft Palate Craniofac J 41:381-386.
22. Liu Z, Zhang J, Berg DK. 2007. Role of endogenous nicotinic signaling in guiding neuronal development. Biochem Pharmacol 74:1112-1119.
23. Lorente C, Cordier S, Goujard J, Aymé S, Bianchi F, Calzolari E, De Walle HE, Knill-Jones R. 2000. Tobacco and alcohol use during pregnancy and risk of oral clefts. Occupational exposure and congenital malformation working group. Am J Public Health 90:415-419.
24. Marinucci L, Balloni S, Bodo M, Carinci F, Pezzetti F, Stabellini G, Carmela C, Lumare E. 2009. Patterns of some extracellular matrix gene expression are similar in cells from cleft lip-palate patients and in human palatal fibroblasts exposed to diazepam in culture. Toxicology 257:10-16.
25. Martínez-Sanz E, Del Río A, Barrio C, Murillo J, Maldonado E, Garcillán B, Amoró s M, Fuerte T, Fernández A, Trinidad E, Rabadán MA, López Y, Martínez ML, Martínez- Alvarez C. 2008. Alteration of medial-edge epithelium cell adhesion in two Tgf-beta3 null mouse strains. Differentiation 76:417-430.
26. Meng L, Bian Z, Torensma R, Von den Hoff JW. 2009. Biological mechanisms in palatogenesis and cleft palate. J Dent Res 88:22-33.
27. Murray JC. 2002. Gene/environment causes of cleft lip and/or palate. Clin Genet 61:248-256.
28. Park JW, Cai J, McIntosh I, Jabs EW, Fallin MD, Ingersoll R, Hetmanski JB, Vekemans M, Attie-Bitach T, Lovett M, Scott AF, Beaty TH. 2006. High throughput SNP and expression analyses of candidate genes for non-syndromic oral clefts. J Med Genet 43:598-608.
29. Patterson MK Jr. 1979. Measurement of growth and viability of cells in culture. In: Talby WB, Paston IH, editors. Methods in enzymology, Vol. 58. New York: Academic Press. pp 141-152.
30. Proetzel G, Pawlowski SA,Wiles MV, Yin M, Boivin GP, Howles PN, Ding J, Ferguson MW, Doetschman T. 1995. Transforming growth factor-beta 3 is required for secondary palate fusion. Nat Genet 11:409-414.
31. Roman J, Ritzenthaler JD, Gil-Acosta A, Rivera HN, Roser-Page S. 2004. Nicotine and fibronectin expression in lung fibroblasts: Implications for tobacco-related lung tissue remodeling. FASEB J 18:1436-1438.
32. Schutte BC, Murray JC. 1999. The many faces and factors of orofacial clefts. Hum Mol Genet 8:1853-1859.
33. Scott DA, Stapleton JA, Palmer RM, Wilson RF, Sutherland G, Coward PY, Gustavsson G, Odell EW, Poston RN. 2000. Plasma concentrations of reputed tumor-associated soluble CD44 isoforms (v5 and v6) in smokers are dose related and decline on smoking cessation. Cancer Epidemiol Biomarkers Prev 9:1211-1214.
34. Shaw GM, Carmichael SL, Vollset SE, Yang W, Finnell RH, Blom H, Midttun Ø, Ueland PM. 2009. Mid-pregnancy cotinine and risks of orofacial clefts and neural tube defects. J Pediatr 154:17-29.
35. Sherman L, Wainwright D, Ponta H, Herrlich P. 1998. A splice variant of CD44 expressed in the apical ectodermal ridge presents fibroblast growth factors to limb mesenchyme and is required for limb outgrowth. Genes Dev 12:1058-1071.
36. Silver MH, Foidart JM, Pratt RM. 1981. Distribution of fibronectin and collagen during mouse limb and palate development. Differentiation 18:141-149.
37. Warrington A, Vieira AR, Christensen K,Orioli IM, Castilla EE, Romitti PA, Murray JC. 2006. Genetic evidence for the role of loci at 19q13 in cleft lip and palate. J Med Genet 43:e26.
38. Wessler I, Kilbinger H, Bittinger F, Unger R, Kirkpatrick CJ. 2003. The non-neuronal cholinergic system in humans: Expression, function and pathophysiology. Life Sci 72:2055-2061.
39. Yoshiura K, Machida J, Daack-Hirsch S, Patil SR, Ashworth LK, Hecht JT, Murray JC. 1998. Characterization of a novel gene disrupted by a balanced chromosomal translocation t(2;19)(q11.2;q13.3) in a family with cleft lip and palate. Genomics 54:231-240.
40. Zia S, Ndoye A, Lee TX, Webber RJ, Grando SA. 2000. Receptor-mediated inhibition of keratinocyte migration by nicotine involves modulations of calcium influx and intracellular concentration. J Pharmacol Exp Ther 293:973-981.